Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MYASTHENIA GRAVIS DISEASE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MYASTHENIA GRAVIS DISEASE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL MYASTHENIA GRAVIS DISEASE
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL MYASTHENIA GRAVIS DISEASE MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDIACTION
11.3 PHARACOLOGICAL CLASS OD THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.1 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DISEASE TYPE
15.1 OVERVIEW
15.2 OCULAR MYASTHENIA GRAVIS
15.3 GENERALIZED MYASTHENIA GRAVIS
15.3.1 MILD GENERALIZED
15.3.2 MODERATE GENERALIZED
15.3.3 SEVERE GENERALIZED
15.4 CONGENITAL MYASTHENIC SYNDROMES (CMS)
15.5 TRANSIENT NEONATAL MYASTHENIA GRAVIS
15.6 JUVENILE MYASTHENIA GRAVIS
16 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY TREATMENT TYPE
16.1 OVERVIEW
16.2 MEDICATION
16.2.1 CHOLINESTERASE INHIBITORS
16.2.1.1. PYRIDOSTIGMINE
16.2.1.2. NEOSTIGMINE
16.2.2 IMMUNOSUPPRESSANTS
16.2.2.1. CORTICOSTEROIDS (E.G., PREDNISONE)
16.2.2.2. NON-STEROIDAL IMMUNOSUPPRESSANTS
16.2.2.2.1. AZATHIOPRINE
16.2.2.2.2. OTHERS
16.2.3 MONOCLONAL ANTIBODIES
16.2.3.1. ANTI-CD20 MONOCLONAL ANTIBODIES (E.G., RITUXIMAB)
16.2.3.2. COMPLEMENT INHIBITORS
16.2.3.2.1. ECULIZUMAB
16.2.3.2.2. OTHERS
16.2.3.3. FCRN ANTAGONISTS (E.G., EFGARTIGIMOD)
16.2.4 EMERGING DRUGS
16.3 SURGICAL TREATMENT
16.3.1 THYMECTOMY
16.3.1.1. OPEN THYMECTOMY
16.3.1.2. MINIMALLY INVASIVE THYMECTOMY
16.4 PLASMAPHERESIS AND INTRAVENOUS IMMUNOGLOBULIN (IVIG)
16.4.1 PLASMAPHERESIS
16.4.2 IVIG
16.4.2.1. POLYCLONAL IVIG
16.4.2.2. SUBCUTANEOUS IVIG
16.5 EMERGING THERAPIES
16.5.1 GENE THERAPY
16.5.2 CELL THERAPY
16.5.3 TARGETED IMMUNOTHERAPIES
17 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DIAGNOSIS
17.1 OVERVIEW
17.2 EDROPHONIUM TEST
17.3 BLOOD TEST
17.4 REPETITIVE NERVE STIMULATION
17.5 SINGLE-FIBER ELECTROMYOGRAPHY (EMG)
17.6 OTHERS
18 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.3 PARENTERAL
18.4 SUBCUTANEOUS
18.5 OTHERS
19 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DOSAGE FORM
19.1 OVERVIEW
19.2 TABLET
19.3 CAPSULE
19.4 INJECTABLE
19.5 OTHER
20 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY AGE GROUP
20.1 OVERVIEW
20.2 PEDIATRIC
20.3 ADULTS
20.4 GERIATRIC
21 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY GENDER
21.1 OVERVIEW
21.2 MALE
21.3 FEMALE
22 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 GENERAL HOSPITALS
22.2.2 SPECIALTY HOSPITALS
22.3 CLINICS
22.3.1 NEUROLOGY CLINICS
22.3.2 SPECIALTY MYASTHENIA GRAVIS TREATMENT CENTERS
22.4 HOMECARE SETTINGS
22.5 RESEARCH AND ACADEMIC INSTITUTES
23 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 HOSPITAL
23.3 PHARMACIES
23.4 RETAIL PHARMACIES
23.5 ONLINE PHARMACIES
23.6 SPECIALTY PHARMACIES
24 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, SWOT AND DBMR ANALYSIS
25 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, BY REGION
GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 U.K.
26.2.3 ITALY
26.2.4 FRANCE
26.2.5 SPAIN
26.2.6 RUSSIA
26.2.7 SWITZERLAND
26.2.8 TURKEY
26.2.9 BELGIUM
26.2.10 NETHERLANDS
26.2.11 DENMARK
26.2.12 SWEDEN
26.2.13 POLAND
26.2.14 NORWAY
26.2.15 FINLAND
26.2.16 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 CHINA
26.3.3 SOUTH KOREA
26.3.4 INDIA
26.3.5 SINGAPORE
26.3.6 THAILAND
26.3.7 INDONESIA
26.3.8 MALAYSIA
26.3.9 PHILIPPINES
26.3.10 AUSTRALIA
26.3.11 NEW ZEALAND
26.3.12 VIETNAM
26.3.13 TAIWAN
26.3.14 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 EGYPT
26.5.3 BAHRAIN
26.5.4 UNITED ARAB EMIRATES
26.5.5 KUWAIT
26.5.6 OMAN
26.5.7 QATAR
26.5.8 SAUDI ARABIA
26.5.9 REST OF MEA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL MYASTHENIA GRAVIS DISEASE MARKET, COMPANY PROFILE
27.1 ALEXION PHARMACEUTICALS
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 ARGENX
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 UCB PHARMA
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 IMMUNOVANT
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 JANSSEN PHARMACEUTICALS (JOHNSON & JOHNSON)
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 HORIZON THERAPEUTICS
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 CATALYST PHARMACEUTICALS
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 TG THERAPEUTICS
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 MITSUBISHI TANABE PHARMA CORPORATION
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 APELLIS PHARMACEUTICALS
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 NOVARTIS
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 ASTELLAS PHARMA
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ADAMIS PHARMACEUTICALS CORPORATION
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 CURAVAC
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 SHANGHAI PHARMACEUTICALS
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 BIOHAVEN PHARMACEUTICALS
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
